{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:40:00Z","timestamp":1789720800587,"version":"4.0.1"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC 12331018"],"award-info":[{"award-number":["NSFC 12331018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bull Math Biol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s11538-024-01329-6","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T03:32:42Z","timestamp":1723001562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mathematical Modeling of Tumor Immune Interactions: The Role of Anti-FGFR and Anti-PD-1 in the Combination Therapy"],"prefix":"10.1007","volume":"86","author":[{"given":"Chenghang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-6760","authenticated-orcid":false,"given":"Jinzhi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"issue":"4","key":"1329_CR1","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4161\/cc.8.4.7657","volume":"8","author":"VD Acevedo","year":"2009","unstructured":"Acevedo VD, Ittmann M, Spencer DM (2009) Paths of FGFR-driven tumorigenesis. Cell Cycle 8(4):580\u2013588. https:\/\/doi.org\/10.4161\/cc.8.4.7657","journal-title":"Cell Cycle"},{"issue":"7463","key":"1329_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC et al (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415\u2013421. https:\/\/doi.org\/10.1038\/nature12477","journal-title":"Nature"},{"issue":"19","key":"1329_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","volume":"35","author":"AB Apolo","year":"2017","unstructured":"Apolo AB, Infante JR, Balmanoukian A et al (2017) Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol 35(19):2117\u20132124. https:\/\/doi.org\/10.1200\/JCO.2016.71.6795","journal-title":"J Clin Oncol"},{"key":"1329_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae131","author":"T Arulraj","year":"2024","unstructured":"Arulraj T, Wang H, Ippolito A et al (2024) Leveraging multi-omics data to empower quantitative systems pharmacology in immuno-oncology. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbae131","journal-title":"Brief Bioinform"},{"issue":"5","key":"1329_CR5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina IS, Turner NC (2017) Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer 17(5):318\u2013332. https:\/\/doi.org\/10.1038\/nrc.2017.8","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1329_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"F Balkwill","year":"2009","unstructured":"Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9(5):361\u2013371. https:\/\/doi.org\/10.1038\/nrc2628","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1329_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J (2019) Transforming growth factor-$$\\beta $$ signaling in immunity and cancer. Immunity 50(4):924\u2013940. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.024","journal-title":"Immunity"},{"key":"1329_CR8","doi-asserted-by":"publisher","first-page":"1258388","DOI":"10.3389\/fimmu.2023.1258388","volume":"14","author":"DJ Benjamin","year":"2023","unstructured":"Benjamin DJ, Hsu R (2023) Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy. Front Immunol 14:1258388. https:\/\/doi.org\/10.3389\/fimmu.2023.1258388","journal-title":"Front Immunol"},{"issue":"21","key":"1329_CR9","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1158\/1078-0432.CCR-19-2300","volume":"26","author":"JS Bergholz","year":"2020","unstructured":"Bergholz JS, Wang Q, Kabraji S et al (2020) Integrating immunotherapy and targeted therapy in cancer treatment: mechanistic insights and clinical implications. Clin Cancer Res 26(21):5557\u20135566. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2300","journal-title":"Clin Cancer Res"},{"key":"1329_CR10","doi-asserted-by":"publisher","unstructured":"Biot C, Rentsch CA, Gsponer JR et\u00a0al (2012) Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med 4(137):137ra72. https:\/\/doi.org\/10.1126\/scitranslmed.3003586","DOI":"10.1126\/scitranslmed.3003586"},{"issue":"1","key":"1329_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/onci.1.1.17884","volume":"1","author":"R Breban","year":"2012","unstructured":"Breban R, Bisiaux A, Biot C et al (2012) Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response. OncoImmunology 1(1):9\u201317. https:\/\/doi.org\/10.4161\/onci.1.1.17884","journal-title":"OncoImmunology"},{"key":"1329_CR12","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1002\/mma.5536","volume":"42","author":"C Burgos-Sim\u00f3n","year":"2019","unstructured":"Burgos-Sim\u00f3n C, Garc\u00eda-Medina N, Mart\u00ednez-Rodr\u00edguez D et al (2019) Mathematical modeling of the dynamics of the bladder cancer and the immune response applied to a patient: evolution and short-term prediction. Math Methods Appl Sci 42:5746\u20135757","journal-title":"Math Methods Appl Sci"},{"issue":"7492","key":"1329_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315\u2013322. https:\/\/doi.org\/10.1038\/nature12965","journal-title":"Nature"},{"issue":"3","key":"1329_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/bib\/bbv012","volume":"17","author":"A Cappuccio","year":"2016","unstructured":"Cappuccio A, Tieri P, Castiglione F (2016) Multiscale modelling in immunology: a review. Brief Bioinform 17(3):408\u2013418. https:\/\/doi.org\/10.1093\/bib\/bbv012","journal-title":"Brief Bioinform"},{"key":"1329_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbs.2022.108868","volume":"350","author":"Y Chen","year":"2022","unstructured":"Chen Y, Lai X (2022) Modeling the effect of gut microbiome on therapeutic efficacy of immune checkpoint inhibitors against cancer. Math Biosci 350:108868. https:\/\/doi.org\/10.1016\/j.mbs.2022.108868","journal-title":"Math Biosci"},{"issue":"1","key":"1329_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"issue":"12","key":"1329_CR17","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1084\/jem.20030152","volume":"198","author":"W Chen","year":"2003","unstructured":"Chen W, Jin W, Hardegen N et al (2003) Conversion of peripheral CD4$$^+$$ CD25$$^-$$ Naive T cells to CD4$$^+$$ CD25$$^+$$ regulatory T cells by TGF-$$\\beta $$ induction of transcription factor Foxp3. J Exp Med 198(12):1875\u20131886. https:\/\/doi.org\/10.1084\/jem.20030152","journal-title":"J Exp Med"},{"issue":"13","key":"1329_CR18","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1158\/0008-5472.CAN-16-3338","volume":"77","author":"LM Colli","year":"2017","unstructured":"Colli LM, Machiela MJ, Zhang H et al (2017) Landscape of combination immunotherapy and targeted therapy to improve cancer management. Cancer Res 77(13):3666\u20133671. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3338","journal-title":"Cancer Res"},{"issue":"2","key":"1329_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15(2):81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"1329_CR20","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamaoncol.2019.0413","volume":"5","author":"D Davar","year":"2019","unstructured":"Davar D, Kirkwood JM (2019) PD-1 immune checkpoint inhibitors and immune-related adverse events: understanding the upside of the downside of checkpoint blockade. JAMA Oncol 5(7):942\u2013943. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0413","journal-title":"JAMA Oncol"},{"issue":"17","key":"1329_CR21","doi-asserted-by":"publisher","first-page":"7950","DOI":"10.1158\/0008-5472.CAN-05-0564","volume":"65","author":"LG de Pillis","year":"2005","unstructured":"de Pillis LG, Radunskaya AE, Wiseman CL (2005) A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res 65(17):7950\u20137958. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0564","journal-title":"Cancer Res"},{"issue":"9","key":"1329_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nri1684","volume":"5","author":"T Decker","year":"2005","unstructured":"Decker T, M\u00fcller M, Stockinger S (2005) The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol 5(9):675\u2013687. https:\/\/doi.org\/10.1038\/nri1684","journal-title":"Nat Rev Immunol"},{"key":"1329_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","volume":"39","author":"C Dong","year":"2021","unstructured":"Dong C (2021) Cytokine regulation and function in T cells. Annu Rev Immunol 39:51\u201376. https:\/\/doi.org\/10.1146\/annurev-immunol-061020-053702","journal-title":"Annu Rev Immunol"},{"key":"1329_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA, Ascierto PA, Darcy PK et al (2017) Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 81:116\u2013129. https:\/\/doi.org\/10.1016\/j.ejca.2017.01.035","journal-title":"Eur J Cancer"},{"issue":"3","key":"1329_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00205575","volume":"20","author":"KA Foon","year":"1985","unstructured":"Foon KA, Sherwin SA, Abrams PG et al (1985) A phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immunother 20(3):193\u2013197. https:\/\/doi.org\/10.1007\/BF00205575","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1329_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","volume":"19","author":"A Friedlaender","year":"2022","unstructured":"Friedlaender A, Subbiah V, Russo A et al (2022) EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Rev Clin Oncol 19(1):51\u201369. https:\/\/doi.org\/10.1038\/s41571-021-00558-1","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1329_CR27","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s11538-017-0254-9","volume":"80","author":"A Friedman","year":"2018","unstructured":"Friedman A, Hao W (2018) The role of exosomes in pancreatic cancer microenvironment. Bull Math Biol 80(5):1111\u20131133. https:\/\/doi.org\/10.1007\/s11538-017-0254-9","journal-title":"Bull Math Biol"},{"issue":"12","key":"1329_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","volume":"37","author":"A Gardner","year":"2016","unstructured":"Gardner A, Ruffell B (2016) Dendritic cells and cancer immunity. Trends Immunol 37(12):855\u2013865. https:\/\/doi.org\/10.1016\/j.it.2016.09.006","journal-title":"Trends Immunol"},{"issue":"12","key":"1329_CR29","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel HL, Mercurio AM (2013) VEGF targets the tumour cell. Nat Rev Cancer 13(12):871\u2013882. https:\/\/doi.org\/10.1038\/nrc3627","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1329_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134\u2013144. https:\/\/doi.org\/10.1056\/NEJMoa1305133","journal-title":"N Engl J Med"},{"issue":"7","key":"1329_CR31","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","volume":"37","author":"PE Hughes","year":"2016","unstructured":"Hughes PE, Caenepeel S, Wu LC (2016) Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol 37(7):462\u2013476. https:\/\/doi.org\/10.1016\/j.it.2016.04.010","journal-title":"Trends Immunol"},{"issue":"10","key":"1329_CR32","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/ni1516","volume":"8","author":"PE Jensen","year":"2007","unstructured":"Jensen PE (2007) Recent advances in antigen processing and presentation. Nat Immunol 8(10):1041\u20131048. https:\/\/doi.org\/10.1038\/ni1516","journal-title":"Nat Immunol"},{"issue":"1","key":"1329_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","volume":"82","author":"W Jing","year":"2022","unstructured":"Jing W, Wang G, Cui Z et al (2022) FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res 82(1):114\u2013129. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2362","journal-title":"Cancer Res"},{"key":"1329_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.mce.2015.12.007","volume":"422","author":"KE Johnson","year":"2016","unstructured":"Johnson KE, Makanji Y, Temple-Smith P et al (2016) Biological activity and in vivo half-life of pro-activin A in male rats. Mol Cell Endocrinol 422:84\u201392. https:\/\/doi.org\/10.1016\/j.mce.2015.12.007","journal-title":"Mol Cell Endocrinol"},{"key":"1329_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155479","volume":"142","author":"I Karagiannidis","year":"2021","unstructured":"Karagiannidis I, Salataj E, Said Abu Egal E et al (2021) G-CSF in tumors: aggressiveness, tumor microenvironment and immune cell regulation. Cytokine 142:155479. https:\/\/doi.org\/10.1016\/j.cyto.2021.155479","journal-title":"Cytokine"},{"issue":"2","key":"1329_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","volume":"16","author":"M Katoh","year":"2019","unstructured":"Katoh M (2019) Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol 16(2):105\u2013122. https:\/\/doi.org\/10.1038\/s41571-018-0115-y","journal-title":"Nat Rev Clin Oncol"},{"key":"1329_CR37","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ et al (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090331","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"1329_CR38","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2217\/imt-2021-0042","volume":"13","author":"N Khalife","year":"2021","unstructured":"Khalife N, Chahine C, Kordahi M et al (2021) Urothelial carcinoma in the era of immune checkpoint inhibitors. Immunotherapy 13(11):953\u2013964. https:\/\/doi.org\/10.2217\/imt-2021-0042","journal-title":"Immunotherapy"},{"issue":"11","key":"1329_CR39","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/ni1102-999","volume":"3","author":"HT Khong","year":"2002","unstructured":"Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of tumor escape phenotypes. Nat Immunol 3(11):999\u20131005. https:\/\/doi.org\/10.1038\/ni1102-999","journal-title":"Nat Immunol"},{"issue":"8","key":"1329_CR40","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","volume":"27","author":"JM Kim","year":"2016","unstructured":"Kim JM, Chen DS (2016) Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure). Ann Oncol 27(8):1492\u20131504. https:\/\/doi.org\/10.1093\/annonc\/mdw217","journal-title":"Ann Oncol"},{"issue":"3","key":"1329_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s002850050127","volume":"37","author":"D Kirschner","year":"1998","unstructured":"Kirschner D, Panetta JC (1998) Modeling immunotherapy of the tumor-immune interaction. J Math Biol 37(3):235\u2013252. https:\/\/doi.org\/10.1007\/s002850050127","journal-title":"J Math Biol"},{"issue":"10","key":"1329_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1008234","volume":"16","author":"E Koz\u0142owska","year":"2020","unstructured":"Koz\u0142owska E, Suwi\u0144ski R, Giglok M et al (2020) Mathematical model predicts response to chemotherapy in advanced non-resectable non-small cell lung cancer patients treated with platinum-based doublet. PLoS Comput Biol 16(10):e1008234. https:\/\/doi.org\/10.1371\/journal.pcbi.1008234","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"1329_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF02460644","volume":"56","author":"VA Kuznetsov","year":"1994","unstructured":"Kuznetsov VA, Makalkin IA, Taylor MA et al (1994) Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull Math Biol 56(2):295\u2013321. https:\/\/doi.org\/10.1007\/BF02460644","journal-title":"Bull Math Biol"},{"issue":"1","key":"1329_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12918-017-0446-9","volume":"11","author":"X Lai","year":"2017","unstructured":"Lai X, Friedman A (2017) Combination therapy for melanoma with BRAF\/MEK inhibitor and immune checkpoint inhibitor: a mathematical model. BMC Syst Biol 11(1):70. https:\/\/doi.org\/10.1186\/s12918-017-0446-9","journal-title":"BMC Syst Biol"},{"issue":"5","key":"1329_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178479","volume":"12","author":"X Lai","year":"2017","unstructured":"Lai X, Friedman A (2017) Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: a mathematical model. PLoS ONE 12(5):e0178479. https:\/\/doi.org\/10.1371\/journal.pone.0178479","journal-title":"PLoS ONE"},{"issue":"21","key":"1329_CR46","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1073\/pnas.1721559115","volume":"115","author":"X Lai","year":"2018","unstructured":"Lai X, Stiff A, Duggan M et al (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci USA 115(21):5534\u20135539. https:\/\/doi.org\/10.1073\/pnas.1721559115","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"1329_CR47","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nri3088","volume":"11","author":"T Lawrence","year":"2011","unstructured":"Lawrence T, Natoli G (2011) Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 11(11):750\u2013761. https:\/\/doi.org\/10.1038\/nri3088","journal-title":"Nat Rev Immunol"},{"key":"1329_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.biosystems.2020.104319","volume":"200","author":"T Lazebnik","year":"2021","unstructured":"Lazebnik T, Aaroni N, Bunimovich-Mendrazitsky S (2021) PDE based geometry model for BCG immunotherapy of bladder cancer. Biosystems 200:104319. https:\/\/doi.org\/10.1016\/j.biosystems.2020.104319","journal-title":"Biosystems"},{"issue":"7","key":"1329_CR49","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141(7):1117\u20131134. https:\/\/doi.org\/10.1016\/j.cell.2010.06.011","journal-title":"Cell"},{"issue":"19","key":"1329_CR50","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K et al (2020) Bladder cancer: a review. JAMA 324(19):1980\u20131991","journal-title":"JAMA"},{"issue":"5","key":"1329_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09488","volume":"8","author":"J Li","year":"2022","unstructured":"Li J, Wu J, Zhang J et al (2022) A multicompartment mathematical model based on host immunity for dissecting COVID-19 heterogeneity. Heliyon 8(5):e09488. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09488","journal-title":"Heliyon"},{"key":"1329_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbs.2022.108911","volume":"353","author":"KL Liao","year":"2022","unstructured":"Liao KL, Watt KD (2022) Mathematical modeling for the combination treatment of IFN-$$\\gamma $$ and anti-PD-1 in cancer immunotherapy. Math Biosci 353:108911. https:\/\/doi.org\/10.1016\/j.mbs.2022.108911","journal-title":"Math Biosci"},{"issue":"2","key":"1329_CR53","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/10430340252769716","volume":"13","author":"VWY Lui","year":"2002","unstructured":"Lui VWY, He Y, Falo L et al (2002) Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum Gene Ther 13(2):177\u2013185. https:\/\/doi.org\/10.1089\/10430340252769716","journal-title":"Hum Gene Ther"},{"issue":"3","key":"1329_CR54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00285-023-01872-1","volume":"86","author":"S Ma","year":"2023","unstructured":"Ma S, Lei J, Lai X (2023) Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy. J Math Biol 86(3):38. https:\/\/doi.org\/10.1007\/s00285-023-01872-1","journal-title":"J Math Biol"},{"issue":"2","key":"1329_CR55","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4111\/kju.2010.51.2.94","volume":"51","author":"YH Maeng","year":"2010","unstructured":"Maeng YH, Eun SY, Huh JS (2010) Expression of fibroblast growth factor receptor 3 in the recurrence of non-muscle-invasive urothelial carcinoma of the bladder. Korean J Urol 51(2):94\u2013100. https:\/\/doi.org\/10.4111\/kju.2010.51.2.94","journal-title":"Korean J Urol"},{"key":"1329_CR56","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ctrv.2016.09.018","volume":"50","author":"R Morales-Barrera","year":"2016","unstructured":"Morales-Barrera R, Su\u00e1rez C, de Castro AM et al (2016) Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: new direction and new hope. Cancer Treat Rev 50:208\u2013216. https:\/\/doi.org\/10.1016\/j.ctrv.2016.09.018","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"1329_CR57","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8(12):958\u2013969. https:\/\/doi.org\/10.1038\/nri2448","journal-title":"Nat Rev Immunol"},{"key":"1329_CR58","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1600-065X.2008.00706.x","volume":"226","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Zhang X (2008) Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226:205\u2013218. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00706.x","journal-title":"Immunol Rev"},{"issue":"2","key":"1329_CR59","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/gt.2008.156","volume":"16","author":"C Mueller","year":"2009","unstructured":"Mueller C, Braag SA, Martino AT et al (2009) The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a Cftr$$-\/-$$-dependent allergy mouse model. Gene Ther 16(2):172\u2013183. https:\/\/doi.org\/10.1038\/gt.2008.156","journal-title":"Gene Ther"},{"issue":"2","key":"1329_CR60","doi-asserted-by":"publisher","first-page":"137","DOI":"10.30707\/LiB5.2Nikolopoulou","volume":"5","author":"E Nikolopoulou","year":"2018","unstructured":"Nikolopoulou E, Johnson LR, Harris D et al (2018) Tumour-immune dynamics with an immune checkpoint inhibitor. Lett Biomath 5(2):137\u2013159","journal-title":"Lett Biomath"},{"issue":"1","key":"1329_CR61","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49\u201361. https:\/\/doi.org\/10.1016\/j.immuni.2014.06.010","journal-title":"Immunity"},{"key":"1329_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/cso2.1019","author":"K Okuneye","year":"2021","unstructured":"Okuneye K, Bergman D, Bloodworth JC et al (2021) A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer. Comput Syst Oncol. https:\/\/doi.org\/10.1002\/cso2.1019","journal-title":"Comput Syst Oncol"},{"issue":"2","key":"1329_CR63","first-page":"115","volume":"12","author":"JC Oliver","year":"1993","unstructured":"Oliver JC, Bland LA, Oettinger CW et al (1993) Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res 12(2):115\u2013120","journal-title":"Lymphokine Cytokine Res"},{"issue":"5","key":"1329_CR64","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD (2020) Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin 70(5):404\u2013423. https:\/\/doi.org\/10.3322\/caac.21631","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"1329_CR65","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974\u20131982. https:\/\/doi.org\/10.1200\/JCO.2014.59.4358","journal-title":"J Clin Oncol"},{"issue":"7528","key":"1329_CR66","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558\u2013562. https:\/\/doi.org\/10.1038\/nature13904","journal-title":"Nature"},{"issue":"3","key":"1329_CR67","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazi\u00e8res J, Planchard D et al (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16(3):257\u2013265. https:\/\/doi.org\/10.1016\/S1470-2045(15)70054-9","journal-title":"Lancet Oncol"},{"issue":"3","key":"1329_CR68","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H et al (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171(3):540\u2013556. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007","journal-title":"Cell"},{"key":"1329_CR69","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jtbi.2011.10.027","volume":"294","author":"M Robertson-Tessi","year":"2012","unstructured":"Robertson-Tessi M, El-Kareh A, Goriely A (2012) A mathematical model of tumor-immune interactions. J Theor Biol 294:56\u201373. https:\/\/doi.org\/10.1016\/j.jtbi.2011.10.027","journal-title":"J Theor Biol"},{"issue":"12","key":"1329_CR70","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41573-020-0086-4","volume":"19","author":"MI Rosenbaum","year":"2020","unstructured":"Rosenbaum MI, Clemmensen LS, Bredt DS et al (2020) Targeting receptor complexes: a new dimension in drug discovery. Nat Rev Drug Discov 19(12):884\u2013901. https:\/\/doi.org\/10.1038\/s41573-020-0086-4","journal-title":"Nat Rev Drug Discov"},{"issue":"6512","key":"1329_CR71","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1126\/science.abe0955","volume":"370","author":"SG Rozen","year":"2020","unstructured":"Rozen SG (2020) Mutational selection in normal urothelium. Science 370(6512):34\u201335. https:\/\/doi.org\/10.1126\/science.abe0955","journal-title":"Science"},{"issue":"4","key":"1329_CR72","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.immuni.2008.02.017","volume":"28","author":"YP Rubtsov","year":"2008","unstructured":"Rubtsov YP, Rasmussen JP, Chi EY et al (2008) Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28(4):546\u2013558. https:\/\/doi.org\/10.1016\/j.immuni.2008.02.017","journal-title":"Immunity"},{"issue":"1","key":"1329_CR73","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamaoncol.2016.4574","volume":"3","author":"R Santana-Davila","year":"2017","unstructured":"Santana-Davila R, Bhatia S, Chow LQM (2017) Harnessing the immune system as a therapeutic tool in virus-associated cancers. JAMA Oncol 3(1):106\u2013112. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4574","journal-title":"JAMA Oncol"},{"issue":"1","key":"1329_CR74","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cyto.2014.10.031","volume":"74","author":"A Saxena","year":"2015","unstructured":"Saxena A, Khosraviani S, Noel S et al (2015) Interleukin-10 paradox: a potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine 74(1):27\u201334. https:\/\/doi.org\/10.1016\/j.cyto.2014.10.031","journal-title":"Cytokine"},{"issue":"10105","key":"1329_CR75","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390(10105):1853\u20131862. https:\/\/doi.org\/10.1016\/S0140-6736(17)31601-X","journal-title":"Lancet"},{"issue":"10","key":"1329_CR76","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41585-019-0226-y","volume":"16","author":"AK Schneider","year":"2019","unstructured":"Schneider AK, Chevalier MF, Derr\u00e9 L (2019) The multifaceted immune regulation of bladder cancer. Nat Rev Urol 16(10):613\u2013630. https:\/\/doi.org\/10.1038\/s41585-019-0226-y","journal-title":"Nat Rev Urol"},{"key":"1329_CR77","doi-asserted-by":"publisher","first-page":"9653873","DOI":"10.1155\/2018\/9653873","volume":"2018","author":"L Shaikhet","year":"2018","unstructured":"Shaikhet L, Bunimovich-Mendrazitsky S (2018) Stability analysis of delayed immune response BCG infection in bladder cancer treatment model by stochastic perturbations. Comput Math Methods Med 2018:9653873. https:\/\/doi.org\/10.1155\/2018\/9653873","journal-title":"Comput Math Methods Med"},{"issue":"2","key":"1329_CR78","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205\u2013214. https:\/\/doi.org\/10.1016\/j.cell.2015.03.030","journal-title":"Cell"},{"issue":"6","key":"1329_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252620","volume":"16","author":"N Siewe","year":"2021","unstructured":"Siewe N, Friedman A (2021) TGF-beta inhibition can overcome cancer primary resistance to PD-1 blockade: a mathematical model. PLoS ONE 16(6):e0252620. https:\/\/doi.org\/10.1371\/journal.pone.0252620","journal-title":"PLoS ONE"},{"issue":"1","key":"1329_CR80","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41467-022-28509-z","volume":"13","author":"AK Singh","year":"2022","unstructured":"Singh AK, Praharaj M, Lombardo KA et al (2022) Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer. Nat Commun 13(1):878. https:\/\/doi.org\/10.1038\/s41467-022-28509-z","journal-title":"Nat Commun"},{"issue":"2","key":"1329_CR81","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","volume":"48","author":"LK Smith","year":"2018","unstructured":"Smith LK, Boukhaled GM, Condotta SA et al (2018) Interleukin-10 directly inhibits CD8$$^+$$ T cell function by enhancing N-glycan branching to decrease antigen sensitivity. Immunity 48(2):299\u2013312. https:\/\/doi.org\/10.1016\/j.immuni.2018.01.006","journal-title":"Immunity"},{"key":"1329_CR82","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jtbi.2016.01.026","volume":"394","author":"L Soto-Ortiz","year":"2016","unstructured":"Soto-Ortiz L, Finley SD (2016) A cancer treatment based on synergy between anti-angiogenic and immune cell therapies. J Theor Biol 394:197\u2013211. https:\/\/doi.org\/10.1016\/j.jtbi.2016.01.026","journal-title":"J Theor Biol"},{"issue":"10","key":"1329_CR83","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski R, Li P, Leonard WJ (2018) Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol 18(10):648\u2013659. https:\/\/doi.org\/10.1038\/s41577-018-0046-y","journal-title":"Nat Rev Immunol"},{"key":"1329_CR84","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fphys.2020.00151","volume":"11","author":"KM Storey","year":"2020","unstructured":"Storey KM, Lawler SE, Jackson TL (2020) Modeling oncolytic viral therapy, immune checkpoint inhibition, and the complex dynamics of innate and adaptive immunity in glioblastoma treatment. Front Physiol 11:151. https:\/\/doi.org\/10.3389\/fphys.2020.00151","journal-title":"Front Physiol"},{"issue":"1","key":"1329_CR85","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S (2017) Regulatory T cells in cancer immunotherapy. Cell Res 27(1):109\u2013118. https:\/\/doi.org\/10.1038\/cr.2016.151","journal-title":"Cell Res"},{"issue":"1","key":"1329_CR86","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/path.2207","volume":"213","author":"DC Tomlinson","year":"2007","unstructured":"Tomlinson DC, Baldo O, Harnden P et al (2007) FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 213(1):91\u201398. https:\/\/doi.org\/10.1002\/path.2207","journal-title":"J Pathol"},{"issue":"26","key":"1329_CR87","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"issue":"2","key":"1329_CR88","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran L, Xiao JF, Agarwal N et al (2021) Advances in bladder cancer biology and therapy. Nat Rev Cancer 21(2):104\u2013121. https:\/\/doi.org\/10.1038\/s41568-020-00313-1","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1329_CR89","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3(2):133\u2013146. https:\/\/doi.org\/10.1038\/nri1001","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1329_CR90","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/imr.12204","volume":"261","author":"SK Tripathi","year":"2014","unstructured":"Tripathi SK, Lahesmaa R (2014) Transcriptional and epigenetic regulation of T-helper lineage specification. Immunol Rev 261(1):62\u201383. https:\/\/doi.org\/10.1111\/imr.12204","journal-title":"Immunol Rev"},{"issue":"11","key":"1329_CR91","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nri3905","volume":"15","author":"DC Tscharke","year":"2015","unstructured":"Tscharke DC, Croft NP, Doherty PC et al (2015) Sizing up the key determinants of the CD8(+) T cell response. Nat Rev Immunol 15(11):705\u2013716. https:\/\/doi.org\/10.1038\/nri3905","journal-title":"Nat Rev Immunol"},{"issue":"7528","key":"1329_CR92","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568\u2013571. https:\/\/doi.org\/10.1038\/nature13954","journal-title":"Nature"},{"issue":"6721","key":"1329_CR93","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/17826","volume":"397","author":"L Ulloa","year":"1999","unstructured":"Ulloa L, Doody J, Massagu\u00e9 J (1999) Inhibition of transforming growth factor-$$\\beta $$\/SMAD signalling by the interferon-$$\\gamma $$\/STAT pathway. Nature 397(6721):710\u2013713. https:\/\/doi.org\/10.1038\/17826","journal-title":"Nature"},{"issue":"12","key":"1329_CR94","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrurol.2015.231","volume":"12","author":"KEM van Kessel","year":"2015","unstructured":"van Kessel KEM, Zuiverloon TCM, Alberts AR et al (2015) Targeted therapies in bladder cancer: an overview of in vivo research. Nat Rev Urol 12(12):681\u2013694. https:\/\/doi.org\/10.1038\/nrurol.2015.231","journal-title":"Nat Rev Urol"},{"issue":"4","key":"1329_CR95","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrurol.2017.172","volume":"15","author":"RC Walshaw","year":"2018","unstructured":"Walshaw RC, Honeychurch J, Illidge TM et al (2018) The anti-PD-1 era\u2013an opportunity to enhance radiotherapy for patients with bladder cancer. Nat Rev Urol 15(4):251\u2013259. https:\/\/doi.org\/10.1038\/nrurol.2017.172","journal-title":"Nat Rev Urol"},{"issue":"1","key":"1329_CR96","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41698-023-00405-9","volume":"7","author":"H Wang","year":"2023","unstructured":"Wang H, Arulraj T, Kimko H et al (2023) Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition. NPJ Precis Oncol 7(1):55. https:\/\/doi.org\/10.1038\/s41698-023-00405-9","journal-title":"NPJ Precis Oncol"},{"issue":"8","key":"1329_CR97","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1080\/08820139.2022.2118606","volume":"51","author":"DF Ward Grados","year":"2022","unstructured":"Ward Grados DF, Ahmadi H, Griffith TS et al (2022) Immunotherapy for bladder cancer: latest advances and ongoing clinical trials. Immunol Invest 51(8):2226\u20132251. https:\/\/doi.org\/10.1080\/08820139.2022.2118606","journal-title":"Immunol Invest"},{"issue":"1","key":"1329_CR98","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM et al (2020) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20(1):7\u201324. https:\/\/doi.org\/10.1038\/s41577-019-0210-z","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1329_CR99","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/cancers12051181","volume":"12","author":"M Wo\u0142\u0105cewicz","year":"2020","unstructured":"Wo\u0142\u0105cewicz M, Hrynkiewicz R, Grywalska E et al (2020) Immunotherapy in bladder cancer: current methods and future perspectives. Cancers (Basel) 12(5):1181","journal-title":"Cancers (Basel)"},{"key":"1329_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2023.111489","volume":"568","author":"L Xue","year":"2023","unstructured":"Xue L, Zhang H, Zheng X et al (2023) Treatment of melanoma with dendritic cell vaccines and immune checkpoint inhibitors: a mathematical modeling study. J Theor Biol 568:111489. https:\/\/doi.org\/10.1016\/j.jtbi.2023.111489","journal-title":"J Theor Biol"},{"issue":"5","key":"1329_CR101","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","volume":"19","author":"H Yamaguchi","year":"2022","unstructured":"Yamaguchi H, Hsu JM, Yang WH et al (2022) Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol 19(5):287\u2013305. https:\/\/doi.org\/10.1038\/s41571-022-00601-9","journal-title":"Nat Rev Clin Oncol"},{"key":"1329_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.amc.2019.06.037","volume":"362","author":"JL Yu","year":"2019","unstructured":"Yu JL, Jang SRJ (2019) A mathematical model of tumor-immune interactions with an immune checkpoint inhibitor. Appl Math Comput 362:124523","journal-title":"Appl Math Comput"},{"issue":"5","key":"1329_CR103","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.immuni.2009.05.001","volume":"30","author":"L Zhou","year":"2009","unstructured":"Zhou L, Chong MMW, Littman DR (2009) Plasticity of CD4$$^+$$ T cell lineage differentiation. Immunity 30(5):646\u2013655. https:\/\/doi.org\/10.1016\/j.immuni.2009.05.001","journal-title":"Immunity"},{"issue":"5","key":"1329_CR104","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","volume":"112","author":"J Zhu","year":"2008","unstructured":"Zhu J, Paul WE (2008) CD4 T cells: fates, functions, and faults. Blood 112(5):1557\u20131569. https:\/\/doi.org\/10.1182\/blood-2008-05-078154","journal-title":"Blood"}],"container-title":["Bulletin of Mathematical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11538-024-01329-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11538-024-01329-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11538-024-01329-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T19:09:20Z","timestamp":1724094560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11538-024-01329-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1007\/s11538-024-01329-6","relation":{},"ISSN":["0092-8240","1522-9602"],"issn-type":[{"value":"0092-8240","type":"print"},{"value":"1522-9602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"116"}}